- Conditions
- Post-Acute COVID-19 Syndrome
- Interventions
- Keytruda
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Long COVID clinical trials
Directory of U.S. ClinicalTrials.gov public records for Long COVID. Browse Long COVID recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Long COVID studies are organized in the registry
Terminology for this condition is unusually inconsistent across the registry: the same kind of study may be filed under “long COVID,” “post-acute sequelae of SARS-CoV-2,” the abbreviation PASC, or “post-COVID conditions.” Trying more than one of these terms is the single most effective way to avoid missing records.
- 69% of the 39 locally indexed Long COVID records are currently marked recruiting.
- The most common phase group in the local index is Not applicable (15 records).
- The most frequent sponsor is Icahn School of Medicine at Mount Sinai (4 records).
- The most listed study location is Boston, Massachusetts (6 records).
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Phase distribution
Top locations
Top sponsors
Top therapies
Live official records
Open in full search- Conditions
- Post-Concussion Syndrome, COVID Long-Haul, COVID-19
- Interventions
- percutaneous electrical nerve-field stimulation, PENFS, percutaneous electrical nerve-field stimulation, PENFS (sham device), percutaneous electrical nerve-field stimulation, PENFS (COVID active device)
- Device
- Lead sponsor
- Children's Hospital of Orange County
- Other
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
- Interventions
- Active tDCS, Sham tDCS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- COVID-19
- Interventions
- Not listed
- Lead sponsor
- Huntington Memorial Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Healthy Participants
- Interventions
- S-892216-LAI, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Cypress, California • Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Acute and Long Term Effects of COVID-19 on Systemic Inflammation, Acute and Long Term Effects of COVID-19 on Lung Function, Acute and Long Term Effects of COVID-19 on Cardiac Function, Acute and Long Term Effects of COVID-19 on Kidney Function, Acute and Long Term Effects of COVID-19 on Brain Function
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- ME/CFS, Long COVID, PASC
- Interventions
- Pyridostigmine, Low-Dose Naltrexone, Placebo
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
- Interventions
- IV normal saline, IV immunoglobulin
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Covid19, MIS-C Associated With COVID-19, MIS-C Multisystem Inflammatory Syndrome in Children, SARS-CoV2 Infection
- Interventions
- Not listed
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 1,097 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Long COVID
- Interventions
- Fluvoxamine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Interventions
- Structured Pacing, Usual Care
- Behavioral · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Long COVID
- Interventions
- Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- Douglas D. Fraser
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California
About this Long COVID clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Long COVID as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Long COVID.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Long COVID.